CHAPEL HILL, N.C.--(BUSINESS WIRE)--Aug. 27, 2009--
POZEN Inc. (NASDAQ: POZN) announced today that John
R. Plachetka, Pharm.D., the company’s chairman, president and chief
executive officer, will present at the Thomas Weisel Partners 2009
Healthcare Conference on Thursday, September 10, 2009 at 3:50 p.m. (ET),
at the Four Seasons Hotel in Boston. Dr. Plachetka’s presentation will
be webcast and archived on POZEN’s home page at www.pozen.com.
POZEN is a pharmaceutical company committed to developing therapeutic
advancements for diseases with unmet medical needs where it can improve
efficacy, safety, and/or patient convenience. POZEN’s efforts are
focused primarily on the development of pharmaceutical products for the
treatment of acute and chronic pain and other pain-related conditions.
POZEN has development and commercialization alliances with
GlaxoSmithKline for Treximet®, which was
approved in 2008 by the United States Food and Drug Administration for
the acute treatment of migraine attacks, with or without aura, in
adults, and with AstraZeneca for VIMOVO™, the proposed trade name for
the proprietary fixed dose combination of naproxen with the proton pump
inhibitor esomeprazole magnesium in a single tablet for conditions such
as osteoarthritis and rheumatoid arthritis in patients who are at risk
for developing NSAID-associated gastric ulcers. The Company’s common
stock is traded on The NASDAQ Stock Market under the symbol “POZN”. For
detailed company information, including copies of this and other press
releases, see POZEN’s website: www.pozen.com.
Source: POZEN Inc.
Bill Hodges, Chief Financial Officer